Exercise tolerance in patients with heart failure--how should it be measured?
- PMID: 2009893
- DOI: 10.1093/oxfordjournals.eurheartj.a059824
Exercise tolerance in patients with heart failure--how should it be measured?
Abstract
The exercise capability of 12 patients with heart failure was investigated by a variety of different methods before and after treatment with the vasodilator flosequinan. Two treadmill protocols were used, a modified Bruce with incremental workloads and a fixed workload protocol. On placebo, mean exercise time was greater with the Bruce protocol, 526 (64) s, than with the fixed protocol, 359 (59) s, P less than 0.005. Flosequinan increased exercise time more with the fixed protocol, so after 5 weeks' treatment exercise time was the same with both protocols; 680 (64) s with the Bruce and 673 (147) s with the fixed protocol. When the results are expressed as work, the patients achieved less with the Bruce protocol, 7.8 (1.9) kJ, than with the fixed protocol 12.5 (1.5) kJ on placebo, P less than 0.01. After flosequinan, the respective values were 14.5 (2.8) and 25.3 (5.1) kJ. Flosequinan improved corridor walk test times but there was no relationship between this and either treadmill test. Pedometer scores of customary activity were unchanged by flosequinan and were not correlated with any other exercise test. Different methods of assessing exercise capability provide different measures of patients' incapacity.
Similar articles
-
Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.Heart Vessels. 1992;7(3):133-40. doi: 10.1007/BF01744866. Heart Vessels. 1992. PMID: 1500398 Clinical Trial.
-
A comparison of the effects of captopril and flosequinan in patients with severe heart failure.Cardiovasc Drugs Ther. 1992 Oct;6(5):465-70. doi: 10.1007/BF00055602. Cardiovasc Drugs Ther. 1992. PMID: 1450090 Clinical Trial.
-
Long-term evaluation of treatment for chronic heart failure: a 1 year comparative trial of flosequinan and captopril.Cardiovasc Drugs Ther. 1994 Dec;8(6):829-36. doi: 10.1007/BF00877401. Cardiovasc Drugs Ther. 1994. PMID: 7742261 Clinical Trial.
-
Flosequinan.Lancet. 1993 Mar 20;341(8847):733-6. doi: 10.1016/0140-6736(93)90498-6. Lancet. 1993. PMID: 8095635 Review. No abstract available.
-
Pharmacology of flosequinan.Am Heart J. 1991 Mar;121(3 Pt 1):974-83. doi: 10.1016/0002-8703(91)90229-b. Am Heart J. 1991. PMID: 2000776 Review.
Cited by
-
The role of exercise testing in the evaluation and management of heart failure.Postgrad Med J. 1999 Aug;75(886):453-8. doi: 10.1136/pgmj.75.886.453. Postgrad Med J. 1999. PMID: 10646020 Free PMC article. Review.
-
Challenges and opportunities for measuring physical activity in sedentary adults.Sports Med. 2001 Feb;31(2):91-100. doi: 10.2165/00007256-200131020-00002. Sports Med. 2001. PMID: 11227981 Review.
-
Effects of motivation of the patient on indices of exercise capacity in chronic heart failure.Br Heart J. 1994 Feb;71(2):162-5. doi: 10.1136/hrt.71.2.162. Br Heart J. 1994. PMID: 8130025 Free PMC article.
-
Phosphodiesterase III inhibitors for heart failure.Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD002230. doi: 10.1002/14651858.CD002230.pub2. Cochrane Database Syst Rev. 2005. PMID: 15674893 Free PMC article.
-
The control of adrenergic function in heart failure: therapeutic intervention.Heart Fail Rev. 2000 Mar;5(1):101-14. doi: 10.1023/A:1009854325711. Heart Fail Rev. 2000. PMID: 16228919 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical